The case for & against
Bull & Bear analysis
Bullish
Pelthos Therapeutics, Inc. (NASDAQ: PLTH) is a developing biopharmaceutical company that focuses on innovative dermatological treatments for pediatric patients, specifically their lead product Zelsudmi, aimed at molluscum contagiosum. The company is strategically positioned in the value chain to address unmet medical needs through at-home treatment options and has shown significant progress with ambitious product expansions and marketing initiatives. Pelthos is part of the ongoing trend toward patient-centered care and increasing demand for accessible therapeutic options.
Bull says
- ↑Q1 ’26 revenue $10.7M (+17% QoQ) on 25% prescription unit growth
- ↑Sales force expanded to 64 reps (+28%), boosting market coverage
- ↑Unique at-home molluscum contagiosum treatment drives adoption
- ↑Strong liquidity with $32M cash runway supports expansion
- ↑Positive momentum and growth factors underpin bullish sentiment
- ↑Effective debt use maintains stability amid scaling
Bear says
- ↓Net loss narrowed to $10.2M in Q1 ’26 despite revenue gains
- ↓SG&A expenses at $21.1M pressure margins and cash burn
- ↓Dependence on Zelsudmi risks revenue if demand softens
- ↓Gross-to-net rate of 29.1% may fluctuate, impacting profits
- ↓Intense dermatology competition could erode market share
- ↓Negative analyst revisions reflect cautious earnings outlook
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-20-2026bullish
Transcript signals
Bull points
- For the first quarter of 2026, we reported 10.7 million of net product revenue, representing a 17% increase from the fourth quarter of 2025.
- In summary, our performance since the launch of Zalesumi in July of 2025 has exceeded our expectations. Furthermore, since launch, we have strengthened our balance sheet and believe we are well-positioned to continue our commercial execution story, bringing a much-needed treatment to Molluscum patients.
- For Q1 2026, shipments and prescriptions were ahead of expectations.
Bear points
- Net loss for the first quarter of 2026 was 10.2 million as compared to 21.7 million for the fourth quarter of 2025, whereas adjusted EBITDA for the first quarter of 2026 was a negative 8.0 million as compared to a negative 7.6 million for the fourth quarter of 2025.
- We saw it in our studies, even in our studies that didn't impact efficacy. You know, there, there may be that they may not be using as much as the dosing card, you know, indicates to use.
- there are a lot of patients not seeking treatment.
Read full transcript analysis ›